Business
Simulations Plus Releases IPFsym version 1A, State-of-the-Art Quantitative Systems Pharmacology (QSP) Software for Idiopathic Pulmonary Fibrosis (IPF)
IPFsym will enable new software and services revenue by aiding development of IPF therapies LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc.
About this update from Simulations Plus, Inc.
[{"type":"text","content":"\nIPFsym will enable new software and services revenue by aiding development of IPF therapies\n\n LANCASTER, Calif.--(BUSINESS WIRE)--\nSimulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has released IPFsym version 1A, quantitative systems pharmacology modeling software to support the development of treatments for idiopathic pulmonary fibrosis. IPF is the most common type of pulmonary fibrosis, a disease that causes scarring (fibrosis) of the lungs. The development effort leading up to this release was sponsored by a leading pharmaceutical company that is also utilizing the software for evaluation of several IPF treatment options.\n\nDr. Scott Q Siler, chief scientific officer of the DILIsym Services division, said, “Finding treatments that provide maximal benefit to IPF patients has proven challenging thus far. We believe that IPFsym can contribute by using the predictive power of the software to accelerate the development of new treatments or combinations of treatments that could halt disease progression and reduce mortality rates for IPF patients.”\n\nShawn O’Connor, chief executive officer of Simulations Plus, added, “Drug development spending on IPF candidates has increased significantly in response to the current global IPF treatment market size estimated to be in excess of $2 billion and growing. The combination of IPFsym and our scientific consulting expertise is positioned to support our clients in this important field.”\n\nFeatures of IPFsym v1A include:\n\n\nRepresentations of key IPF elements, such as:\n\n\nlung fibrosis, lung alveolar epithelial injury, inflammation, and lung function tests;\n\n\nclinically distinct regions of the lungs, including honeycombed regions, fibroblastic foci, and normal alveolar parenchyma;\n\n\n\n\nA virtual IPF population (SimPops®) of greater than 700 subjects with heterogeneity, including variability in disease progression rates;\n\n\nImportant biomarkers or endpoints, including:\n\n\nforced vital capacity (FVC);\n\n\ndiffusing capacity of the lungs for carbon monoxide (DLCO);\n\n\nhigh-resolution computed tomography (HRCT) of the lungs;\n\n\n\n\nStandard of care treatments for IPF patients, including:\n\n\nOFEV® (nintedanib)\n\n\nEsbriet® (pirfenidone)\n\n\n\n\nSimul...